# ScoreItem: Genitália feminina

**ID:** `019bf31d-2ef0-7616-8f7b-33b1c9d11279`
**FullName:** Genitália feminina (Histórico de doenças - Histórico de saúde (Questionar ativamente sobre doenças/sintomas - passado ou atual):)
**Gender:** female

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 11 artigos
- Avg Similarity: 0.558

---

## Contexto

Você é um especialista em medicina funcional integrativa e está contribuindo com o **Escore Plenya** — um escore completo de análise de saúde que avalia todos os aspectos da saúde, performance e longevidade humana. Cada ScoreItem representa um parâmetro clínico, laboratorial, genético, comportamental ou histórico que compõe esse escore.

Seu papel é gerar conteúdo clínico de alta qualidade para enriquecer cada parâmetro do escore com relevância clínica, orientação ao paciente e conduta prática.

**Regras inegociáveis:**
- Use **apenas** o conhecimento médico real consolidado e os dados presentes nos chunks científicos abaixo
- **Não alucine, não invente** dados, estudos, estatísticas ou referências que não estejam nos chunks ou no seu conhecimento médico estabelecido
- Se um dado específico não constar nos chunks e não for do seu conhecimento consolidado, **não o inclua**
- Seja preciso: prefira omitir a inventar

## Instrução

Com base nos chunks científicos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-7616-8f7b-33b1c9d11279`.**

```json
{
  "score_item_id": "019bf31d-2ef0-7616-8f7b-33b1c9d11279",
  "clinical_relevance": "Texto técnico para médicos (1000-5000 chars): definição fisiológica precisa, valores de referência e interpretação, fisiopatologia resumida, dados epidemiológicos com números concretos, estratificação de risco baseada em evidências.",
  "points": 0,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que é este parâmetro sem jargões, por que é importante para a saúde, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta clínica em Markdown (1000-5000 chars): investigação complementar necessária, critérios de encaminhamento a especialistas, intervenções baseadas em evidências. Use bullet points, seções e negrito."
}
```

**Nota:** `points` deve ser `0` neste item — não calcule pontuação.

---

### Contexto Científico

**ScoreItem:** Genitália feminina (Histórico de doenças - Histórico de saúde (Questionar ativamente sobre doenças/sintomas - passado ou atual):)
**Gênero:** female

**30 chunks de 11 artigos (avg similarity: 0.558)**

### Chunk 1/30
**Article:** Gynecologic Pelvic Examination (2024)
**Journal:** StatPearls Publishing
**Section:** abstract | **Similarity:** 0.746

O exame pélvico ginecológico é um componente crítico do cuidado abrangente à saúde da mulher. Envolve inspeção dos genitais externos, exame especular e palpação bimanual para avaliar estruturas reprodutivas internas. Serve para diagnosticar condições incluindo sangramento anormal, corrimento, dor pélvica, infecções e tumores; rastreamento de malignidades; e monitoramento da saúde reprodutiva. A única contraindicação absoluta é a falta de consentimento informado. Diretrizes de organizações como ACOG e ACP variam quanto a exames de rotina em mulheres assintomáticas, com evidências recentes sugerindo benefício limitado para detecção de câncer ovariano, porém o exame pode detectar precocemente cânceres vulvares ou vaginais tratáveis. Complicações incluem desconforto, ansiedade ou trauma mucoso, especialmente em pacientes com vaginite atrófica ou histórico de trauma.

---

### Chunk 2/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** discussion | **Similarity:** 0.639

owdiscussionandreviewofhistologyresults.PhysicalexaminationofthepatientInformedconsentisapre-requisiteforallexaminations,investi-gationsandtreatments.Consentisparticularlyimportantforintimateexaminationsoftheanogenitalarea.Achaperone
shouldbeofferedinallcasesandthisshouldbedocumented
clearlyinthepatientrecords.Theproposedexaminationshould
beadequatelyexplainedtopatientsbeforetheyundress.All
attemptsshouldbemadetomaintainpatients’dignity,provid-
ingprivacytodressandundress,andkeepingthemcoveredas
muchaspossible.Appropriatefacilitiesandequipmentforinvestigationsshouldbeavailablepriortocommencingtheexamination.Theroomshouldbewelllit,privateandsound-
proofed,withasuitableexaminationcouchofadjustable
height.1DermatosesandSTIsmayco-existorawomanwithapre-existingdermatosismaycontractanSTI.Screeningforsexually
transmittedinfections(STI)shouldbeconsideredinallpatients,
dependingonsymptomsandriskfactors.Ifthepatientpresentswithvulvalitch,particularlywithincreaseddischarge,vulvovagi-nalcandidia

---

### Chunk 3/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.593

74
).Notwithstandingtheseﬁndings,HCPsmayposeverysimplequestionstofacilitateanopenconversationonurogenital
healthandtorecordthevarietyofvaginal,vulvarandurinarysymptoms.Visualvaginal,vulvarandpelvicassessmentbyHCPs
isausefulmeasurefordiagnosingVVA/GSMandassessing
responsetotreatment.Moreover,itmayhelpHCPstoidentify
womenatriskofvaginaldrynessanddyspareunia,andallow
themtoproactivelyengageinconversationsaboutsexualhealth(
75
).Figure1reportsaverysimplecheck-listtodiagnoseVVA/GSMinroutineclinicalpractice.WomenwithbreastcancerandothergynecologicalmalignanciesareatveryhighriskofVVAandassociated
symptoms.Indeed,endocrinechemotherapy,surgeryand/or
FrontiersinEndocrinology|www.frontiersin.org4August2019|Volume10|Article561

Nappietal.VaginalHealthandAging
FIGURE1|Averysimplecheck-listtodiagnoseVVA/GSMinroutineclinicalpractice.

---

### Chunk 4/30
**Article:** Mastologia III (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.585

luto, evitar alarmismo, e definir critérios para exames complementares (ressonância) apenas quando houver fatores de risco adicionais.
- [ ] 4. Atualizar materiais educativos para esclarecer que história familiar, por si só, não contraindica reposição; incorporar achados do Sister Study e WHI.
- [ ] 5. Estabelecer diretriz interna: não indicar reposição hormonal sistêmica em pacientes com histórico de câncer de mama; considerar terapias tópicas para atrofia vaginal após tentativa de métodos não hormonais, com suporte emocional.
- [ ] 6. Criar protocolo de uso criterioso de gestrinona em endometriose e mastalgia refratária, com consentimento informado sobre lacunas de evidência oncológica.
- [ ] 7. Definir critérios de indicação de testosterona por motivos não oncológicos, evitando prescrição para “redução de risco mamário” até que haja validação em guidelines.
- [ ] 8.

---

### Chunk 5/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.584

ningforsexually
transmittedinfections(STI)shouldbeconsideredinallpatients,
dependingonsymptomsandriskfactors.Ifthepatientpresentswithvulvalitch,particularlywithincreaseddischarge,vulvovagi-nalcandidiasisshouldbeexcluded.Ifthesymptomsarenot
relievedbyanti-candidaltreatment,especiallyifculturesareneg-
ativeforcandida,thenafullgenitalexaminationincludinga
speculumexamination2shouldbeundertakenunlessdonerecently,andothercausesconsidered.Possiblealternatediagno-
sesincludelichensclerosus,lichenplanus,lichensimplexchron-
icus,psoriasisoraneoplasticcondition(particularlyHPV-relatedvulvalintra-epithelialneoplasiainyoungwomen).Sexualdysfunctionshouldbeconsideredandassessedifappropriatein
allpatients,eitherasthecauseofthesymptomsordeveloped
secondarytothesymptoms.ConditionswhereSTItestingshouldbespeciﬁcallyconsid-ered,iswhengenitalulcersarepresent,eveninthepresenceofa
dermatosisthatcausesulceration.Inthesecases,testingforher-
pessimplexandsyphilisisrecommended.Additionally,wherelesionsfailtohe

---

### Chunk 6/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.562

enﬂoDW.Vulvodyniaincidenceandremissionratesamongadultwomen:a2-yearfollow-upstudy.ObstetGynecol2008;112:231–237.146LamvuG,AlappattuM,WitzemanK,BishopM,RobinsonM,RapkinA.Patternsinvulvodyniatreatmentsand6-monthoutcomesforwomen
enrolledinthenationalvulvodyniaregistry-anexploratoryprospective
study.JSexMed2018;15:705–715.147P^aquetM,Vaillancourt-MorelM-P,JodouinJ-F,StebenM,BergeronS.Paintrajectoriesandpredictors:a7-yearlongitudinalstudyofwomen
withvulvodynia.JSexMed2019;16:1606–1614.148ElkinsN,HuntJ,ScottKM.Neurogenicpelvicpain.PhysMedRehabilClinNAm2017;28:551–569.149EdwardsSK,BatesCM,LewisF,SethiG,GroverD.2014UKnationalguidelineonthemanagementofvulvalconditions.IntJSTDAIDS2015;26:611–624.150HenzellH,BerzinsK,LangfordJP.Provokedvestibulodynia:currentperspectives.IntJWomensHealth2017;9:631–642.151VincentK,EvansE.Anupdateonthemanagementofchronicpelvicpaininwomen.Anaesthesia2021;76(Suppl4):96–107.152AndrewsJC.Vulvodyniainterventions–systematicreviewandevidencegrading.ObstetG

---

### Chunk 7/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** discussion | **Similarity:** 0.561

7;9:631–642.151VincentK,EvansE.Anupdateonthemanagementofchronicpelvicpaininwomen.Anaesthesia2021;76(Suppl4):96–107.152AndrewsJC.Vulvodyniainterventions–systematicreviewandevidencegrading.ObstetGynecolSurv2011;66:299–315.153Corsini-MuntS,RancourtKM,DubeJP,RossiMA,RosenNO.Vulvo-dynia:aconsiderationofclinicalandmethodologicalresearchchallenges
andrecommendedsolutions.JPainRes2017;10:2425–2436.154RosenNO,BergeronS,PukallCF.Recommendationsforthestudyofvulvarpaininwomen,part2:methodologicalchallenges.JSexMed2020;17:595–602.155MirandaVarellaPereiraG,SorianoMarcolinoM,SilveiraNogueiraReisZ,deCastroV,MonteiroM.Asystematicreviewofdrugtreatmentof©2022EuropeanAcademyofDermatologyandVenereologyJEADV2022
VulvalconditionsEuropeanguideline19

vulvodynia:evidenceofastrongplaceboeffect.BJOGIntJObstetGynaecol2018;125:1216–1224.156WeinbergerJM,HoumanJ,CaronATetal.Femalesexualdysfunctionandtheplaceboeffect:ameta-analysis.ObstetGynecol2018;132:453–458.157FosterDC,KotokMB,HuangL-Setal.Orald

---

### Chunk 8/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.558

2017;26:1069–1076.140LeusinkP,vandePaschS,TeunissenD,LaanET,Lagro-JanssenAL.Therelationshipbetweenvulvovaginalcandidiasisandprovokedvulvo-
dynia:asystematicreview.JSexMed2018;15:1310–1321.141ChampaneriaR,D’AndreaRM,LatthePM.Hormonalcontraceptionandpelvicﬂoorfunction:asystematicreview.IntUrogynecolJ2016;27:709–722.142KhandkerM,BradySS,StewartEG,HarlowBL.Ischronicstressduringchildhoodassociatedwithadult-onsetvulvodynia?JWomensHealth2014;23:649–656.143Corsini-MuntS,BergeronS,RosenNO,BeaulieuN,StebenM.Adyadicperspectiveonchildhoodmaltreatmentforwomenwithprovokedvesti-bulodyniaandtheirpartners:associationswithpainandsexualandpsy-
chosocialfunctioning.JSexRes2017;54:308–318.144BergeronS,ReedBD,WesselmannU,Bohm-StarkeN.Vulvodynia.NatRevDisPrimer2020;6:36.145ReedBD,HaefnerHK,SenA,GorenﬂoDW.Vulvodyniaincidenceandremissionratesamongadultwomen:a2-yearfollow-upstudy.ObstetGynecol2008;112:231–237.146LamvuG,AlappattuM,WitzemanK,BishopM,RobinsonM,RapkinA.Patternsinvulvodyniatreatmen

---

### Chunk 9/30
**Article:** Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: An update to the American Cancer Society cervical cancer screening guideline (2026)
**Journal:** CA: A Cancer Journal for Clinicians
**Section:** abstract | **Similarity:** 0.558

Atualização da diretriz de rastreamento de câncer cervical da American Cancer Society para incluir autocoleta de espécimes vaginais para teste de HPV. Para mulheres de risco médio, recomenda-se iniciar rastreamento aos 25 anos com teste primário de HPV a cada 5 anos até 65 anos. Para teste primário de HPV, espécimes cervicais coletados por clínico são preferidos, mas espécimes vaginais autocoletados são aceitáveis. Quando espécimes vaginais autocoletados são HPV negativos no rastreamento, recomenda-se repetir teste em 3 anos. Para descontinuar rastreamento, recomenda-se que mulheres de risco médio tenham testes primários de HPV negativos ou coteste negativo aos 60 e 65 anos. Esta mudança representa avanço significativo ao aumentar acesso ao rastreamento, particularmente para populações com barreiras ao cuidado tradicional.

---

### Chunk 10/30
**Article:** International Urogynecology consultation chapter 2 committee 3: the clinical evaluation of pelvic organ prolapse including investigations into associated morbidity/pelvic floor dysfunction (2023)
**Journal:** International Urogynecology Journal
**Section:** results | **Similarity:** 0.558

ults and the PRISMA ﬁgure for each are reported in three areas: 1. Clinical physical examination2. The urinary tract (LUTS), and3. The gastrointestinal tract (GIT). Other comorbid conditions such as pain and sexual dysfunc-tion are better evaluated and recorded using patient-reported outcomes, which are covered in a separate manuscript of the IUC [2].Clinical physical examination ofawoman withPOPA review of the existing literature on the examination of a patient with POP and the impact of various parameters on the examination findings was performed. The ini-tial search identiﬁed more than 7,155 abstracts of which around 96 studies were included in the ﬁnal review (Fig.2) This review of the clinical examination is divided into four sections:1. General aspects of examination of a woman with POP2. Examination of the anterior compartment3. Examination of the posterior compartment4.

---

### Chunk 11/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** discussion | **Similarity:** 0.555

alcancerandothermalignancies.Finally,eveniflesscommon,anearlydiagnosisofcancermaybedelayedbyvaginalsynechiaeandhematocolposduetovaginal
occlusion(
80

82
).THEBURDENOFVVA/GSMONWOMEN’S
SEXUALFUNCTIONANDQUALITYOF
LIFE(QOL)
Inthelastdecade,manyinternationalsurveysattemptedto
clarifytheimpactofVVA/GSMonsexualfunctionandQoL
(Table2)indicatingthataproactiveapproachtoconversationsaboutvulvovaginaldiscomfortwouldimprovediagnosisandtreatment(
22
).Eventhoughtheproportionofwomenwhoaresexuallyactivedecreaseswithadvancingage,thevalueofdiscussionsaboutsexualhealthisstillhighinelderlywomenwhoareinpartnership(
83
).InthesurveyofMidlifeDevelopmentintheUnitedStates(MIDUSII)womenwhoweremarried
orcohabitatinghadapproximately8timeshigheroddsof
beingsexuallyactive,withmorethan30%ofwomenover
65yearsreportingsexualactivityatleastonceaweek(
84
).Sexualsatisfactionishighlydependentonmanypsychosocial
aspectsrelatedtowell-being(
85
).Inaddition,dimensionsofsexualresponsearepartofthedominoeﬀectofmenopausal

---

### Chunk 12/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.551

lialchangesandsymptomsofdryness
anddyspareunia(
72
).Inbothclinicalandresearchsettings,subjectiveassessment(theMBSapproach)andobjectiveassessmentsofVVA
(measurementofvaginalmaturationindexandvaginalpH)
shouldbecombinedaccordingtoarecentsystematicliteraturesearch(
73
).EventhoughahighrateofsubjectivesymptomsisassociatedwithaclinicaldiagnosisofVVA/GSMinover90%
ofthecases(
21
),objectivesignsandsubjectivesymptomshaveadiﬀerentprevalencedistributionintheyearsaftermenopause
andarenotstrictlyassociated(
35
).However,self-reportedandvisiblevaginaldrynessdocorrelateandtogetherwith
ph>5,mucosalpallor,andrugaethinningseemtobethemostimportantobjectivesignstomakeadiagnosis(
35
).Ontheotherhand,thepresenceofothervulvarandurinarysignsarerelevanttotheseverityofVVS/GSManditsimpactonwomen’sdaily
living(
74
).Notwithstandingtheseﬁndings,HCPsmayposeverysimplequestionstofacilitateanopenconversationonurogenital
healthandtorecordthevarietyofvaginal,vulvarandurinarysymptoms.Visualvaginal,vulvarandpelvic

---

### Chunk 13/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.550

8.doi:10.1097/GME.000000000000112177.SadovskyR,BassonR,KrychmanM,MoralesAM,SchoverL,WangR,etal.Cancerandsexualproblems.JSexMed.(2010)7:34973.doi:10.1111/j.1743-6109.2009.01620.x78.NappiRE,CucinellaL,MartiniE,RossiM,TiraniniL,MartellaS,etal.Sexualityinprematureovarianinsuﬃciency.Climacteric.(2019)22:28995.doi:10.1080/13697137.2019.157535679.DoumouchtsisSK,ChrysanthopoulouEL.Urogenitalconsequencesinageingwomen.BestPractResClinObstetGynaecol.(2013)27:699714.doi:10.1016/j.bpobgyn.2013.03.007
FrontiersinEndocrinology|www.frontiersin.org9August2019|Volume10|Article561

Nappietal.VaginalHealthandAging
80.BoltonPJ,Selo-OjemeDO.Endometrialadenocarcinoma:anunusualpresentationwithacuteurinaryretentionsecondarytohaematocolpos.JObstetGynaecol.(1999)19:5534.doi:10.1080/0144361996450881.SegalS,HarvieHS,SiegelmanE,AryaLA.Severeatrophicvaginitiscausingvaginalsynechiaeandhematocolposatmenopause.Menopause.(2011)18:3335.doi:10.1097/gme.0b013e3181f3285a82.StilesM,RedmerJ,PaddockE,SchragerS.Gyne

---

### Chunk 14/30
**Article:** Value of pelvic examination in women with pelvic organ prolapse: A systematic review (2024)
**Journal:** International Journal of Gynecology & Obstetrics
**Section:** abstract | **Similarity:** 0.550

Revisão sistemática de 67 estudos sobre valor do exame pélvico em mulheres com prolapso de órgãos pélvicos (POP). Sintomas associados ao prolapso são pobremente correlacionados com diagnóstico de POP, sendo abaulamento vaginal o sintoma com melhor correlação (moderada a boa) com estágio de POP. Os fatores mais fortemente associados com risco de recorrência após cirurgia ou falha de pessário são clínicos, incluindo estágio mais alto de POP antes da cirurgia, avulsão do músculo levantador do ânus, e medidas vaginais e genitais. Conclui-se que exame pélvico (especular vaginal e exame digital vaginal) pode confirmar presença de POP e identificar fatores de risco para falha de tratamento ou recorrência. Evidência robusta sobre valor diagnóstico e prognóstico do exame físico na avaliação de POP.

---

### Chunk 15/30
**Article:** International Urogynecology consultation chapter 2 committee 3: the clinical evaluation of pelvic organ prolapse including investigations into associated morbidity/pelvic floor dysfunction (2023)
**Journal:** International Urogynecology Journal
**Section:** results | **Similarity:** 0.549

fecography incorrectly performedPhysical examination, POP-QNo signiﬁcant relationship was found between defecatory symptoms and presence of posterior vaginal wall prolapse on examination (p=0.33), rectocele (n=0.19), or enterocele (n=0.99) on defecographyClinical examination may overestimate posterior vaginal wall prolapse and underestimate enteroceleDDIFluoroscopic defecog-raphy with vagina also opaciﬁedClinical examination diagnosis of a rectocele compared with defecographySensitivity 1.0, 95% CI 0.82 to 1Speciﬁcity 0.23 95% CI −0.11 to 0.38Clinical examination diagnosis of enterocele compared with defecographySensitivity 0.07, 95% CI 0.002 to 0.32Speciﬁcity 0.95, 95% CI 0.85 to 0.99No correlation of bowel symptoms with posterior wall prolapse on examination or rectocele or enterocele on defecography

2678
 International Urogynecology Journal (2023) 34:2657–2688
Table 9  (continued)
ReferenceStudy designPopulationMethod(s) of clinical assessmentResultsDiscussionKim etal.

---

### Chunk 16/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** results | **Similarity:** 0.548

ingdermatosis);thiscanpre-
sentwithsymmetricalerythema.InvestigationAbiopsyisrarelynecessarybutoneshouldbeperformedifthere
areatypicalfeaturesorfailuretorespondtotreatment(GRADE1,D).Patchtestingisusefulifanallergiccontactdermatitisissus-pected,butisnotnecessaryforalltypesofdermatitis.Patchtest-ingshouldbeperformedinacliniccompetentinthis
investigationandinterpretationoftheresults(GRADE1,B).Inadditiontothestandardbaselineseriesofallergens,anypatient
withasuspectedvulvalallergiccontactdermatitisshouldbe
testedtomedicaments,preservativesandanyspeciﬁcproducts
appliedbythepatienttothevulva,attheappropriatedilu-
tions.8,9Therelevanceoftheresultsmustbeassessedcarefully,asapositivetestdoesnotnecessarilymeanthatthetestedprod-uctisresponsibleforthevulvalrash.Conversely,anegativetest
cannotcompletelyprovetheinnocenceofatopicallyapplied
product.Appropriateswabswillexcludecandidiasisandbacterialinfection.Skinscrapingswillhelptoruleouttineacruris.Management1Avoidanceofirritantsandpossibleallergens

---

### Chunk 17/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.545

  nalscoredeﬁningthedegreeofatrophyinthe
genitourinarytractbyassigningasinglescoretoeachparameter.Totalscorerangesfrom5to25,withlowerscorescorrespondingtogreaterurogenitalatrophy(
68
).VulvaHealthIndexevaluateslabia,urethra,clitoris,introitusaswellaselasticityandpainduringintercourse;totalscorerangesfrom0to24,withhigherscorescorrespondingwithgreatervulvaratrophy.IftheVulva
HealthIndexisover8orthereisscoreof3(severe)in
anycategory,vulvaratrophyissuggested(
69
).Inthemostseverecases,tissuesmaybeeasilytraumatizedandirritatedbytouchingorinsertingthespeculum(
70
).Organprolapseorhypertonicityofthepelvicﬂoorwithsecondaryvaginismmay
bealsopresent,aswellasvulvovaginalsignswhichrequirea
diﬀerentialdiagnosisbyperformingcolposcopyorcarryingout
bacteriologicalanalyses(
11
).Ingeneral,VVA/GSMistypicallyaclinicaldiagnosisandfewlaboratorytestsmaybeusedtosupporttheevidence.Amongthem,theevaluationofvaginalpHand
thevaginalmaturationindex(VMI)arethemostused(
41
).WiththeVMIitispossibletoidentifythe

---

### Chunk 18/30
**Article:** Lichen sclerosus: The 2023 update (2023)
**Journal:** Frontiers in Medicine
**Section:** results | **Similarity:** 0.544

ween clitoris and urethra and 
in the interlabial sulci, leading to dysuria (
95
). Due to intense pruritus, 
hyperkeratotic lesions and ecchymoses in the involved regions can 
beobserved. Mostly, clitoral hood, labia minora, inner part of labia 
majora, perineum and perianal region is aected (
Figure2B
), sometimes 
resembling gure of eight, also termed keyhole or hourglass, with 
involvement of vulvar and perianal regions. Progression of disease can 
lead to scarring, which is observed in 80% of adult female patients and 
30% of girls (
11
). Scarring oen results in fusion or even complete 
resorption of labia minora and loss of clitoral hood. In addition, 
narrowing of vaginal introitus can occasionally lead to dyspareunia, 
strongly aecting sexual life of the patients (
5
).
In prepubertal girls, the clinical symptoms are similar to that of 
adult females, which oen present itch, soreness and sometimes dysuria.

---

### Chunk 19/30
**Article:** Fisiologia Endócrina Feminina (2024)
**Journal:** Pos Graduacao MFI
**Section:** discussion | **Similarity:** 0.541

incluindo:
  - Fogachos (calores) e sudoreses noturnas; distúrbios do sono/insônia.
  - Ansiedade, depressão, baixa disposição/energia; redução de memória e vitalidade.
  - Dor articular; olho seco; ressecamento vaginal; dispareunia; baixa libido.
  - Alterações menstruais (polimenorreia com ciclos encurtados; períodos de amenorreia).
  - Síndrome geniturinária da pós-menopausa; sintomas urogenitais (incontinência, risco de prolapso).
  - Sarcopenia/perda de massa e tônus muscular.
  - Alterações cutâneas (queda de colágeno; pele mais flácida).
  - Mudanças metabólicas (↑ triglicérides, colesterol, leptina).
- Discussão sobre declínio da fertilidade com a idade, janela ótima de maternidade entre 20–30 anos e postergação da maternidade.
## Objetivo:
- Não há exame físico, laboratoriais ou de imagem de uma paciente específica.

---

### Chunk 20/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** discussion | **Similarity:** 0.540

llenge since it is unrevealed by females, underdiagnosed
by healthcare professionals, and consequently undertreated. Around 50% of postmenopausal females have
experienced vaginal discomfort caused by VVA 
[10]
. VVA is a long-standing disorder that has a substantial
effect on the quality of life and sexual health. Females are generally unaware of this, as well as the possibility
of effective and safe treatments. Women with VVA are more likely to have genitourinary problems and
female sexual dysfunction. Due to this, it is crucial to incorporate VVA in the menopause agenda by
promoting an honest and reasonable discussion about intimacy and, if necessary, performing a
gynecological pelvic examination. The vaginal "taboo" must be broken, suggesting the latest
recommendations for the proper treatment of VVA in clinical setups, to enhance the well-being of older
women 
[10]
.

---

### Chunk 21/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** methods | **Similarity:** 0.539

y. Given its relationship with urogynecological conditions, this
study will help to evaluate both subjectively and objectively the incidence of symptoms related to VVA and
its effects on the quality of life of postmenopausal women. This will eventually help to understand the need
to address this issue while making postmenopausal women health-related policies. Potential remedies to
overcome the obstacles currently preventing patient-HCP interactions addressing sexual health include
providing communication tools to facilitate the "uncomfortable" conversation, educating women, and
providing enough training for healthcare professionals.
Methods
The current study was conducted at a rural tertiary healthcare center in Central India and is a cross-sectional
study. The study population taken into consideration were all the postmenopausal women between the age
group 45 and 75 years with at least one vulvovaginal symptom attending the Outpatient Department (OPD).

---

### Chunk 22/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** results | **Similarity:** 0.535

Urogenitalageing:anoldproblemnewlyrecognized.Maturitas.(1995)22(Suppl.1):S15.doi:10.1016/0378-5122(95)00956-634.PalmaF,XholliA,CagnacciA,astheWritingGroupoftheAGATAStudy.Themostbothersomesymptomofvaginalatrophy:evidence
fromtheobservationalAGATAstudy.Maturitas.(2018)108:1823.doi:10.1016/j.maturitas.2017.11.00735.PalmaF,VolpeA,VillaP,CagnacciA,WritingGroupofGATAStudy.VaginalAtrophyofWomeninPostmenopause.Resultsfroma
multicentricobservationalstudy:theAGATAstudy.Maturitas.(2016)83:404.doi:10.1016/j.maturitas.2015.09.00136.KingsbergSA,KrychmanM,GrahamS,BernickB,MirkinS.Thewomen’sEMPOWERsurvey:identifyingwomen’sperceptionsonvulvarandvaginalatrophyanditstreatment.JSexMed.(2017)14:41324.doi:10.1016/j.jsxm.2017.01.01037.KingsbergSA,LarkinL,KrychmanM,ParishSJ,BernickB,MirkinS.WISDOMsurvey:attitudesandbehaviorsofphysicianstowardvulvarandvaginalatrophy(VVA)treatmentinwomenincluding
thosewithbreastcancerhistory.Menopause.(2019)26:12431.doi:10.1097/GME.000000000000119438.KingsbergSA,S

---

### Chunk 23/30
**Article:** Study of Vulvovaginal Atrophy and Genitourinary Syndrome of Menopause and Its Impact on the Quality of Life of Postmenopausal Women in Central India (2024)
**Journal:** Cureus
**Section:** results | **Similarity:** 0.534

the Study of Women's Sexual Health and the North American Menopause
Society
. Menopause. 2014, 21:1063-8. 
10.1097/GME.0000000000000329
3
. 
Weber MA, Limpens J, Roovers JP: 
Assessment of vaginal atrophy: a review
. Int Urogynecol J. 2015, 26:15-
28. 
10.1007/s00192-014-2464-0
4
. 
Palacios S, Nappi RE, Bruyniks N, Particco M, Panay N: 
The European Vulvovaginal Epidemiological Survey
(EVES): prevalence, symptoms and impact of vulvovaginal atrophy of menopause
. Climacteric. 2018,
21:286-91. 
10.1080/13697137.2018.1446930
5
. 
Moral E, Delgado JL, Carmona F, et al.: 
The impact of genitourinary syndrome of menopause on well-being,
functioning, and quality of life in postmenopausal women
. Menopause. 2018, 25:1418-23.
10.1097/GME.0000000000001148
6
. 
Palma F, Volpe A, Villa P, Cagnacci A: 
Vaginal atrophy of women in postmenopause. Results from a
multicentric observational study: The AGATA study
. Maturitas. 2016, 83:40-4.
2024 Ulhe et al. Cureus 16(2): e54802.

---

### Chunk 24/30
**Article:** Mastologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.532

dos sintomas gerais a investigar em consulta, como dor mamária e TPM intensa, que podem indicar predominância estrogênica.

## Objetivo:
Não há achados de exame físico de um paciente específico. A abordagem objetiva descrita inclui:
- Avaliação da composição corporal por bioimpedância ou densitometria de corpo total, identificando condições como sarcopenia em mulheres com peso normal.
- Solicitação de exames laboratoriais para avaliar marcadores inflamatórios e verificar se a paciente está metabolicamente doente ou em risco.

## Diagnóstico Primário:
- Avaliação: Discussão educacional sobre estratificação de risco para câncer de mama. 90% dos casos relacionam-se ao estilo de vida e 10% a fatores genéticos conhecidos. Mutações de alta penetrância (ex.: BRCA1, BRCA2, TP53) aumentam significativamente o risco, porém são raras. Epigenética e estilo de vida são cruciais e modificáveis.

---

### Chunk 25/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.531

,inthe
AGATAstudy,whichincludedasampleofItalianwomenasking
foraroutinegynecologicalexamination,aclinicaldiagnosisofVVAdisplayedaprevalencerangingfrom64.7to84.2%,starting
from1to6yearsaftermenopause(
35
).Itisessentialthathealthcareproviders(HCPs)areproactivetouncoverthetopicof
vaginalhealthbecausewomenwhodiscussVVAwithHCPsare
twiceaslikelytobecurrentspeciﬁc-treatmentusers(59.7%ascomparedto22.7%whodidnotdiscussVVA)(
28
).Itisfrequenttoencounteradisconnectionineducation,communication,andinformationbetweenHCPsandtheirmenopausalpatients(
36
).TheWISDOMsurveyoutlinedthatthecomfortlevelofHCPs
whenprescribingVVAtreatmentisstillsuboptimal,inparticularincasetheyarenotgynecologists(
37
).Educationofwomen,adequatetrainingofHCPsandprovisionofcommunicationtoolsinordertofacilitatetheuncomfortabledialoguearepotentialsolutionstoaddressthebarrierscurrentlyimpedingpatientclinicianinteractionsaroundsexualhealth(
38
).Basiccounselingistheﬁrststepinthemanagementofpostmenopausalsexualdysfunctions(

---

### Chunk 26/30
**Article:** International Urogynecology consultation chapter 2 committee 3: the clinical evaluation of pelvic organ prolapse including investigations into associated morbidity/pelvic floor dysfunction (2023)
**Journal:** International Urogynecology Journal
**Section:** results | **Similarity:** 0.528

opic defecography or MRI defecography, but how this relates to clinical decision-making or more speciﬁcally outcomes, remains unclear.2. In patients where these diagnoses are in question or in patients who present with GI symptoms, it is reasonable to obtain further imaging and testing beyond a routine clinical examination. However, these additional studies can be expensive and uncomfortable to patients, and currently there is no apparent beneﬁt to identifying an underlying condition that would inﬂuence treatment decisions and outcomes. Until a beneﬁt is established, their routine use in asymptomatic women with POP should be discouraged outside of research protocols.Further research Future studies comparing imaging and physiological testing with clinical examination need to compare their results with standardized clinical evaluation in the form of the POP-Q.

---

### Chunk 27/30
**Article:** 2021 European guideline for the management of vulval conditions (2022)
**Journal:** Journal of the European Academy of Dermatology and Venereology
**Section:** other | **Similarity:** 0.528

:592–600.135FontaineF,DumoulinC,BergeronSetal.Pelvicﬂoormusclemor-phometryandfunctioninwomenwithprimaryandsecondarypro-
vokedvestibulodynia.JSexMed2018;15:1149–1157.136McLeanL,Thibault-GagnonS,BrooksK,GoldﬁngerC,PukallC,ChamberlainS.Differencesinpelvicmorphologybetweenwomenwith
andwithoutprovokedvestibulodynia.JSexMed2016;13:963–971.137BergeronS,LikesWM,StebenM.Psychosexualaspectsofvulvovaginalpain.BestPractResClinObstetGynaecol2014;28:991–999.138ChisariC,MonajemiMB,ScottW,Moss-MorrisR,McCrackenLM.Psychosocialfactorsassociatedwithpainandsexualfunctioninwomen
withVulvodynia:asystematicreview.EurJPainLondEngl2021;25:39–50.139HarlowBL,CaronRE,ParkerSE,ChatterjeaD,FoxMP,NguyenRHN.Recurrentyeastinfectionsandvulvodynia:canwebelieveassociations
basedonself-reporteddata?JWomensHealth2017;26:1069–1076.140LeusinkP,vandePaschS,TeunissenD,LaanET,Lagro-JanssenAL.Therelationshipbetweenvulvovaginalcandidiasisandprovokedvulvo-
dynia:asystematicreview.JSexMed2018;15:1310–1321.141Champ

---

### Chunk 28/30
**Article:** Mastologia II (2024)
**Journal:** Pos Graduacao MFI
**Section:** methods | **Similarity:** 0.528

; uso de medicamentos/suplementos; hábitos de vida (alimentação, exercício, álcool, tabaco); saúde intestinal; níveis de estresse/ansiedade; rede de apoio.
   - Atenção a sintomas de predominância estrogênica: dor mamária, TPM intensa; lacunas de cuidado em pacientes com alterações fibrocísticas e cistos, frequentemente não acolhidas apesar de sintomas de excesso de estrogênio circulante.
* **Avaliação de composição corporal**
   - Preferência por métodos além da balança: bioimpedância (utilizada pela instrutora) ou densitometria de corpo total.
   - Observação de sarcopenia em mulheres com peso normal e desconhecimento da condição; necessidade de intervenção.
* **Marcadores laboratoriais e metabolicidade**
   - Solicitar marcadores inflamatórios para identificar adoecimento metabólico ou risco, e para monitorar evolução após intervenções.

---

### Chunk 29/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** results | **Similarity:** 0.527

A,Kokot-KierepaM,GoldsteinJ,NappiRE.VaginalhealthintheUnitedStates:resultsfromthevaginalhealth:
insights,views&attitudessurvey.Menopause.(2013)20:10438.doi:10.1097/GME.0b013e318287342d95.NappiRE,KrychmanML.TheAmerican-Europeandiﬀerenceinvulvarandvaginalatrophyviews:alessonfromtheREVIVESurvey.Climacteric.(2016)19:2525.doi:10.3109/13697137.2016.117302696.PastoreLM,CarterRA,HulkaBS,WellsE.Self-reportedurogenitalsymptomsinpostmenopausalwomen:Women’sHealthInitiative.Maturitas.(2004)49:292303.doi:10.1016/j.maturitas.2004.06.01997.GassM,LarsonJ,CochraneB,MansonJE,LaneD,BarnabeiV,etal.SexualactivityandvaginalsymptomsinthepostinterventionphaseoftheWomen’sHealthInitiativeHormoneTherapyTrials.Menopause.(2018)25:25264.doi:10.1097/GME.000000000000099498.Castelo-BrancoC,BigliaN,NappiRE,SchwenkhagenA,PalaciosS.Characteristicsofpost-menopausalwomenwithgenitourinarysyndromeofmenopause:implicationsforvulvovaginalatrophydiagnosisand
treatmentselection.Maturitas.(2015)81:4629.doi:10.1016/j

---

### Chunk 30/30
**Article:** Addressing Vulvovaginal Atrophy (VVA)/Genitourinary Syndrome of Menopause (GSM) for Healthy Aging in Women (2019)
**Journal:** Front Endocrinol (Lausanne)
**Section:** other | **Similarity:** 0.526

ngesoftheurinarysystem(reducedurethralclosurepressure,reducedsensorythresholdinthebladder,and,insomecases,increasedriskofrUTIs)maybeobservedasaconsequenceof
thethinningoftheurinaryepitheliumandweakeningofthe
surroundingtissue(
53
).KEY-ELEMENTSOFVVA/GSMDIAGNOSIS
Clinicalinterviewsandratingscalestoscorethemost
bothersomesymptoms(MBS)(Table1)areusefulinstrumentstomeasuresubjectivesymptomsandtoidentifyriskfactors
forVVA/GSM.Objectivediagnosisisconﬁrmedbyanaccurate
pelvicexamination,includinggentleinspectionofthevulva,vestibule,vagina,andurethrainordertorecognizethesignsofVVA/GSM(Table1)whichcanberatedonvalidatedscales(
67
).TheVaginalHealthIndexScoreisaclinicaltoolthat,byevaluating5parameters(vaginalelasticity,vaginalsecretions,pH,epithelialmucousmembrane,vaginalhydration),allows
toobtainaﬁnalscoredeﬁningthedegreeofatrophyinthe
genitourinarytractbyassigningasinglescoretoeachparameter.Totalscorerangesfrom5to25,withlowerscorescorrespondingtogreaterurogenitalatrophy(
68
).VulvaHealthIn

---

